Ablynx NV has announced that Roger Perlmutter, a director at StemCells Inc and the Immune Design Corp, will be nominated as an independent non-executive director at an extraordinary meeting of shareholders in early November. Dr Perlmutter was previously executive vice president, research and development, at Amgen Inc. Prior to this, he was executive vice president of worldwide basic research and preclinical development at Merck & Co.
Ablynx is also proposing that Russell Greig, a former executive at GlaxoSmithKline Plc and president of SR One, also join the board. Dr Greig is currently chairman of Syntaxin Ltd; AM Pharma BV and Isconova AS.
Ablynx announced the nominations on 27 September 2012.
Copyright 2012 Evernow Publishing Ltd